PRODUCT INFORMATION



Methylscopolamine (bromide)

Item No. 23862

CAS Registry No.:	155-41-9	
Formal Name:	(1α,2β,4β,5α,7β)-7-[(2S)-3-hydroxy-1-	
	oxo-2-phenylpropoxy]-9,9-dimethyl-3- oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, monobromide	НО
Synonyms:	NSC 61809, NSC 120606, U-5036	
MF:	$C_{18}H_{24}NO_4 \bullet Br$	
FW:	398.3	
Purity:	≥98%	• Br-
Supplied as:	A crystalline solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

Methylscopolamine (bromide) is supplied as a crystalline solid. A stock solution may be made by dissolving the methylscopolamine (bromide) in the solvent of choice, which should be purged with an inert gas. Methylscopolamine (bromide) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of methylscopolamine (bromide) in these solvents is approximately 5 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of methylscopolamine (bromide) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of methylscopolamine (bromide) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Methylscopolamine is an antagonist of muscarinic acetylcholine receptors (K_ds = 0.25, 0.37, 0.23, 0.22, and 0.3 nM for M_{1-5} respectively).¹ It inhibits oxotremorine-induced gastric ulcer formation and pupillary light reflex in rats (ED₅₀s = 0.4 and 3.6 µg/kg, respectively).² It also increases pupil diameter in rats with an ED₂₀₀ value of 1.8 µg/kg. Formulations containing methylscopolamine have been used for the treatment of peptic ulcers, intestinal spasms, and motion sickness.

References

- 1. Jakubík, J., Randáková, A., Zimčik, P., et al. Binding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors. Sci. Rep. 7, 40381 (2017).
- 2. Daniotti, S. and Del Soldato, P. Comparative studies of the effects of some antimuscarinic agents on gastric damage and pupillary reflex in the rat. Br. J. Pharmacol. 82(2), 305-307 (1984).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM